Latest Breaking News On - Osaka research center - Page 1 : comparemela.com

Regnase-1 Deletion Boosts Anti-Tumor Activity in NK Cells

Natural killer (NK) cells play a crucial role in the first line of host defense by eliminating bacteria, viruses, and mutated cells that might become

Xin sunDiego diezYasuharu nagahamaShizuo akiraImmunology frontier research center ifreOsaka universityDrug discovery of otsuka pharmaceutical co ltdOsaka research centerImmunology frontier research centerDrug discovery

Boosting Anti-Tumor Activity: Regnase-1 Deletion in NK Cells

Boosting Anti-Tumor Activity: Regnase-1 Deletion in NK Cells
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Yasuharu nagahamaDiego diezShizuo akiraXin sunImmunology frontier research center ifreOsaka universityDrug discovery of otsuka pharmaceutical co ltdOsaka research centerImmunology frontier research centerDrug discovery

Pulling out the stops: Deletion of regnase-1 promotes anti-tumor activity in NK cells

Pulling out the stops: Deletion of regnase-1 promotes anti-tumor activity in NK cells
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Xin sunDiego diezYasuharu nagahamaShizuo akiraDrug discovery of otsuka pharmaceutical co ltdOsaka universityImmunology frontier research center ifreOsaka research centerImmunology frontier research centerDrug discovery

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Francois vigneaultCindy fungToshiki sudoJeffrey gilbertOtsuka pharmaceutical co ltdOsaka research centerDrug discoveryOtsuka pharmaceuticalMedia contact cindy fung

Otsuka, Shape Ink Potential $1 5B Deal to Develop Eye AAV Gene Therapies

To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.

Francois vigneaultToshiki sudoSumitomo pharmaJapan otsuka pharmaceuticals onOsaka research centerOtsuka pharmaceuticalsShape therapeuticsDrug discoveryHape ink potential 1 5b deal to develop eye aav gene therapies